Each of [thirteen] drugs stays or goes in NU584's Unit 8 review mainly by one test: whether its benefit can arrive within a frail man's likely remaining years. Searches like "nu 584 unit 8 assignment example", "nu584 unit 8 sample" and "nu584 unit 8 example" land here.
What a finished NU584 Unit 8 medication burden review looks like
Benefit horizon organizes roughly five pages. Its opening lists the frailty level, Clinical Frailty Scale [6], the prognostic index used with its bracketed estimate, and his stated priority: staying out of the hospital and keeping his mind clear. Three tables follow. Weeks holds drugs whose benefit he feels now: [acetaminophen] for his knees, [tamsulosin], [furosemide] for edema. Months holds [apixaban] for atrial fibrillation and [alendronate]. Years holds [atorvastatin] for primary prevention, [glipizide] pursuing an A1c near [7] percent, a third antihypertensive added to reach a tight target, and [aspirin]. Each row shows the time-to-benefit estimate and its source, any 2023 Beers or STOPP/START version 3 flag, and a proposed action. A START omission gets a row of its own: no laxative beside regular [tramadol].
How a NU584 Unit 8 example is structured
Horizon organizes the review because horizon is what frailty changes. The introduction sets the comparison explicitly: a drug whose benefit takes longer to arrive than his likely remaining time offers mostly risk, and the paper names the prognostic tool and admits its imprecision. Within each band, rows are ordered by harm. The weeks band is mostly kept, with dosing checked. The months band keeps [apixaban], reasoning that stroke prevention accrues quickly and that fall risk alone rarely outweighs it, and questions [alendronate] only on adherence. The years band carries the proposals: [aspirin] stopped, since STOPP flags an antiplatelet beside an anticoagulant without a clear indication; [glipizide] withdrawn in favor of a looser target; the third antihypertensive tapered; [atorvastatin] discussed with him, citing statin time-to-benefit data (Yourman and colleagues, 2021) and how few trial participants were his age. Changes are sequenced across visits.
Prognosis named, with its limits
The index, its inputs and its bracketed estimate appear in the first paragraph, followed by a sentence on imprecision. Every later proposal depends on this estimate, so it is stated openly.
Weeks: benefit he can feel
Symptom drugs mostly stay, because their payoff arrives within days. The review checks their doses against kidney function and adds the missing laxative beside [tramadol].
Months: anticoagulation kept
Stroke prevention in atrial fibrillation begins protecting early, and the review argues that his falls do not by themselves justify stopping [apixaban]. The reasoning is laid out for the prescriber.
Years: where the trimming happens
Tight glucose control, a third blood pressure drug, primary-prevention [aspirin] and a statin all promise benefit on a timescale longer than his estimate. Each is weighed separately, not cut as a group.
Two criteria sets, one column
Beers 2023 and STOPP/START version 3 flags share a column. Where the two agree the case for change is stronger; where only one flags a drug, the review says which and why it still matters.
Where marks go in NU584 Unit 8
Medication burden reviews in NU584 typically reward a paper that ties every decision to time and prognosis, and one that applies Beers flags mechanically, without asking how long each drug takes to help, earns only partial credit. Graders expect the prognostic estimate named and its uncertainty acknowledged; a life expectancy asserted with no source reads as guesswork. Cutting drugs whose benefit is near-term, such as anticoagulation stopped because of falls alone, is marked as an error of its own. START omissions matter as much as STOPP flags, and a missing laxative beside a regular opioid is a classic miss. Both criteria sets should be cited by edition. Proposals presented as orders, all changes made at once, and no attention to the patient's stated priority cost the rest.
Get a NU584 Unit 8 example written to your instructions
Paste every medication in your Unit 8 scenario, with the frailty details and any goals the scenario records, plus the rubric. We place every drug in a benefit-horizon band of weeks, months or years, screen against Beers 2023 and STOPP/START, and write the proposals for the prescriber in a sequence. Free on first request, back in 24-48h.
NU584 Unit 8 questions, answered
What is STOPP/START?
A pair of explicit criteria sets from Europe: STOPP lists potentially inappropriate prescriptions in older adults, and START lists potentially beneficial drugs that are missing. Version 3, published in 2023, is current. It complements the Beers Criteria, and START in particular catches omissions that Beers does not address. Cite the version number in the paper.
Where do time-to-benefit estimates come from?
From analyses of trial data that ask how long it takes for treated patients to show a measurable advantage over controls, such as preventing one event per hundred people treated. Estimates exist for statins, blood pressure control, glucose control and bisphosphonates. Cite the source for each, and note when the trials enrolled few people as old as the patient.
Should a frail patient's anticoagulant be stopped because of falls?
Not on that ground alone, in most analyses. Stroke prevention in atrial fibrillation begins early, and falls rarely shift the balance enough by themselves. The decision depends on bleeding history, kidney function and goals of care, and it belongs to the prescriber with the patient. A paper should show that reasoning instead of assuming falls end the discussion.